S71

Clinical Manifestations and Treatment Considerations of Herpes Simplex

Virus Infection
Anthony Simmons Childrens Hospital, University of Texas Medical Branch at Galveston

Herpes simplex viruses (HSV) types 1 and 2 cause infections manifesting as dermatologic,
immunologic, and neurologic disorders. Some of the most important manifestations and
complications of HSV infection are considered here in a neuroanatomic context. This dis-
cussion should aid in understanding the pathogenesis and, in some cases, diagnosis and man-
agement of associated HSV-related diseases. The sensory nervous system, rather than skin
and mucous membranes, is the primary target of HSV infection. With the intention of ex-
tending the benefits of acyclovir, valacyclovir is now being explored in a number of HSV-
related conditions. This review extends contemporary thinking about how new antiherpetic
drugs might be put to greater therapeutic use in the future.

Downloaded from http://jid.oxfordjournals.org/ by guest on May 18, 2016

Worldwide, 60%95% of the population is infected by one or
more viruses of the herpes viridae family [1]. In an immunocom-
petent host, herpesvirus infections can often cause debilitating
diseases, which may have psychological and physical sequelae in
persons with frequent recurrences [2]. Herpesviruses have two
unique biologic properties: the ability to invade and replicate in
the host nervous system and the ability to establish a site of latent
infection. The neurovirulent properties of herpes simplex virus
(HSV) enable the virus to cause a disease primarily of the sensory
nervous system rather than of the skin [3].
The ability of HSV to lytically infect cells of the central
nervous system (CNS) is illustrated by sporadic cases of po-
tentially fatal HSV encephalitis. In more usual circumstances,
however, the peripheral nervous system is the main target of
the virus [3, 4]. During primary infection, virus is transported
via sensory ganglia to establish a chronic latent infection, most
commonly in the trigeminal, cervical, or lumbosacral ganglia
[5]. Retrograde transport of HSV along nerves and the estab-
lishment of latency are not dependent on viral replication in
the skin or neurons [6] and it therefore follows that neurons
can be infected in the absence of symptoms.
Periodically, HSV may reactivate from its latent state and
virus particles then travel along sensory neurons to the skin
and other mucosal sites to cause recurrent disease episodes.
Recurrent mucocutaneous shedding of HSV can be associated
with lesions or asymptomatic shedding and in either scenario
is allied with a period when virus can be transmitted to a new
host [7, 8]
Acyclovir has been evaluated and is widely used to treat
Financial support: GlaxoWellcome (now GlaxoSmithKline; consultant),
SmithKlineBeecham, Wyeth-Lederle, 3M, Merck.
Reprints or correspondence: Dr. Anthony Simmons, 2.330 Childrens
Hospital, University of Texas Medical Branch at Galveston, 301 University
Blvd., Galveston, TX 77555-0373 (ansimmon@utmb.edu).
The Journal of Infectious Diseases 2002; 186(Suppl 1):S717
2002 by the Infectious Diseases Society of America. All rights reserved.
0022-1899/2002/18608S-0009$15.00
numerous HSV-related conditions (table 1). More recently,
newer nucleoside analogues have been investigated as treat-
ments for HSV infections with the aim of building upon the
success of acyclovir [9]. Valacyclovir is an oral prodrug for-
mulation of acyclovir that provides up to 5 times greater acy-
clovir bioavailability [10]. Although not discussed in this review,
another new medication for herpesvirus infections is famciclo-
vir. In this review of HSV infections (predominantly in im-
munocompetent hosts), I discuss the thought that HSV infec-
tions are a cause of disease primarily of the nervous system
rather than of skin. I also describe the many manifestations of
HSV infection in a neuroanatomic framework to aid in the
understanding of their pathogenesis and management.
Throughout I discuss how newer antiherpetic compounds such
as valacyclovir or famciclovir might help in the discovery of
new associations between HSV and disease.
Infections of the Peripheral Nervous System
The peripheral nervous system is bilaterally symmetric and
segmental in its organization, with a defined dermatome in-
nervated by each cutaneous sensory nerve. An association be-
tween HSV and the peripheral sensory nervous system has been
recognized for some time. Attributing herpetic lesions to in-
dividual dermatomes on the limbs can pose some difficulties
because the distribution of individual nerve roots on the limbs
is less straightforward than on the trunk, owing to rotation of
the limbs during embryogenesis. The simplest way to correct
for the effects of this rotation is to picture the body in the
quadruped position, in which the dermatomes return to a log-
ical, sequential arrangement (figure 1).
Recurrences of HSV infection tend to be confined to the
dermatome of primary infection but do not necessarily occur
at precisely the same anatomic location. In the case of perioral
disease, for example, primary infection is usually inside the
mouth (gingivostomatitis), whereas spread of HSV within the
trigeminal ganglion means that recurrent disease is most com-
S72 Simmons JID 2002;186 (Suppl 1)

monly associated with lesions on the lip (cold sores). Frequency

of recurrence can also depend on the virus subtype (HSV type
1 or type 2) and anatomic sites of infection [11].

Infections of the Trigeminal Nerve

Gingivostomatitis and orolabial HSV infection. Gingivos-

tomatitis is a symptomatic primary HSV-1 infection, usually
occurring in children, and characterized by lesions in and
around the oral cavity. Children are often unable to swallow
because of the associated pain and may become dehydrated.
In severe cases hospitalization may be required and occasionally
autoinoculation can result in conjunctivitis and keratitis. Oral
acyclovir treatment (acyclovir suspension 15 mg/kg 5 times/day
for 7 days) started within the first 3 days of onset of symptoms

Downloaded from http://jid.oxfordjournals.org/ by guest on May 18, 2016

shortens the duration of all clinical manifestations by about
50% [12]. Most cases of gingivostomatitis go untreated, undi-
agnosed, or even unrecognized; the condition is not normally
considered serious.
HSV-1 commonly reactivates from the trigeminal ganglion
to cause the cutaneous and mucocutaneous manifestations of
recurrent facial herpes or cold sores. Cold sores are usually
preceded by prodromal symptoms (e.g., tingling, pain, burning
sensation, or itching at the site of reactivation), which are
thought to be due to early viral replication at sensory nerve
endings and in the epidermis or mucosa [13]. Early initiation
Figure 1. Human cervical (C), thoracic (T), lumbar (L), and sacral
of antiviral therapy is essential since the therapeutic window is (S) dermatomes illustrate the segmental and bilateral symmetric struc-
narrow. Ideally, treatment should begin before a lesion is ap- ture of the peripheral sensory nervous system (shown in quadruped
parent [14, 15]. position).
Cold sores are a common manifestation of HSV infection;
symptomatic outbreaks are estimated to affect 20%40% of tion of valacyclovir during the prodromal period [21]. In con-
adults [16, 17]. Although clinical symptoms are considered mild, trast to the equivocal efficacy of episodic oral acyclovir treat-
frequently recurrent outbreaks are associated with significant ment, suppressive acyclovir (400 mg twice/day) is useful in
morbidity [15]. The benefit of topical treatment of facial herpes preventing recurrent cold sores [22]. Recent data also show that
outbreaks with acyclovir cream is only modest [18, 19]. Simi- oral valacyclovir, administered more conveniently as 500 mg
larly, oral acyclovir appears to offer only limited efficacy on once a day over 4 months, effectively suppresses recurrent her-
lesion healing [20]. The greater bioavailability of valacyclovir pes labialis outbreaks [23].
may, however, translate into an improved clinical benefit in that Recurrences of HSV infection in the distribution of the tri-
some lesions can be aborted by patients initiating administra- geminal nerve have greater impact in circumstances where mu-

Table 1. HSV infections of the peripheral sensory nervous system

Disease manifestation Acyclovir effective? Potential for valacyclovir?

Trigeminal nerve Gingivostomatitis Possible, pediatric formulation required

Recurrent cold sores Controlled trial data available
Corneal infections Possible
Facial resurfacing Possible, limited data available
a
HSV gladiatorum ? Possible, limited data available
7th cranial nerve Facial paralysis Possible
Cervical and thoracic sensory nerves Herpetic whitlow Possible
Nipple infection Possible
Lumbosacral sensory nerves Genital herpes Controlled trial data available
Complications Eczema herpeticum Possible, anecdotal evidence
Erythema multiforme; Possible
Stevens-Johnson
syndrome
a
Can also affect cervical and thoracic sensory nerves.
JID 2002;186 (Suppl 1) Scope of HSV Infections
cocutaneous immune defenses are locally impaired. For ex-
ample, severe recurrences of HSV infection may complicate
laser-resurfacing surgery. Gilbert and McBurney [24], in an un-
controlled study, found that prophylactic valacyclovir (500 mg
twice/day) started either the day before or the day of facial
resurfacing and continued for 14 days thereafter almost com-
pletely eliminated the risk of HSV recurrence following this
procedure. Further controlled trials are needed to optimize the
duration and start time of therapy, together with a dosage reg-
imen of valacyclovir [25].
Ocular HSV infections. HSV is a major cause of corneal
scarring and visual loss, the result not only of a direct viral
cytopathic effect but also an immune-mediated response [26].
In contrast to early antiviral agents, which demonstrated un-
acceptably high levels of systemic toxicity, acyclovir, when in-
troduced almost 20 years ago, was shown to be highly selective
for herpesviruses with low systemic toxicity. Although origi-
nally developed as an ophthalmic ointment formulation outside
the United States, subsequent studies with oral acyclovir
showed good intraocular and tissue penetration [27, 28]. The
low systemic toxicity of acyclovir also made it an ideal can-
didate for long-term use in patients experiencing frequent oc-
ular HSV recurrences.
More recently, a large controlled study investigating long-
term suppressive oral acyclovir therapy for recurrences of HSV
epithelial keratitis and stromal keratitis was reported [29, 30].
This randomized, placebo-controlled trial concluded that acy-
clovir (400 mg twice/day for 12 months) was effective in re-
ducing the rate of recurrences, especially in persons with a prior
history of HSV stromal keratitis. Continuous suppression
rather than intermittent dosing was suggested as the preferred
therapeutic option.
Oral valacyclovir administration provides improved bioa-
vailability of acyclovir, suggesting that valacyclovir should be
evaluated as therapy for ocular HSV infections. In a random-
ized study in which patients about to undergo cataract surgery
received valacyclovir (1000 mg 3 times/day) or acyclovir (800
mg 5 times/day) to achieve steady-state concentrations, acyclo-
vir concentrations in aqueous humor were about 40% of those
in plasma at the same, near maximum, time point [31]. Thus,
intraocular acyclovir concentrations appear to rise in parallel
with plasma concentrations.
Aqueous humor concentrations of acyclovir after valacyclo-
vir administration were almost twice those found after oral
acyclovir (mean SD, 9.18 3.17 vs. 4.59 2.97 mM) and
after valacyclovir dosing exceeded the value of 7.5 mM previ-
ously reported for acyclovir ophthalmic ointment [32]. While
corneal tissue concentrations of acyclovir would be more rel-
evant for assessing the potential efficacy of valacyclovir in oc-
ular HSV disease, acyclovir penetration into ocular fluids after
valacyclovir administration should ensure a substantial excess
given the in vitro IC50 acyclovir susceptibility range of 1 mM
for most HSV-1 strains. Randomized controlled trials evalu-
S73
ating valacyclovir for the acute treatment or prevention of oc-
ular HSV outbreaks are warranted.
Herpetic facial paralysis. Reactivation of HSV-1 from the
geniculate ganglion has been implicated in the pathogenesis of
idiopathic facial palsy or Bells palsy. During the acute phase
of the disease, shedding of HSV-1 into saliva was detectable by
polymerase chain reaction in 40% (n p 47) of cases examined
[33]. Inflammation appears also to play a major role in path-
ogenesis of facial paralysis, and corticosteroids have been a
mainstay of therapy, although views on efficacy remain
controversial.
One study compared acyclovir (400 mg 5 times/day) and
placebo given in combination with oral prednisone and con-
cluded that the combination of acyclovir and prednisone was
more efficacious than oral prednisone alone [34]. A recent meta-
Downloaded from http://jid.oxfordjournals.org/ by guest on May 18, 2016
analysis of prospective trials of steroids, acyclovir, and surgery
for facial palsy identified the complete absence of any ade-
quately powered study. The analysis concluded that, from avail-
able evidence, steroids were probably effective and acyclovir
(with prednisone) was possibly effective in improving facial
function outcome [35]. Clearly, there is a role for antiherpes
therapy in the treatment of this disease; however, several issues
need clarification, including the determination of the propor-
tion of facial palsies attributable to HSV and how they can be
differentiated at the outset from idiopathic (Bells) palsy. Fur-
ther prospective trials are needed that substitute valacyclovir
for acyclovir so as to offer a less cumbersome dosing schedule.
Such a study might also be designed to formally assess the
contribution of corticosteroids in herpetic facial paralysis.
HSV gladiatorum. Another cutaneous manifestation of
HSV infection affecting persons who participate in contact
sports (e.g., wrestling or rugby football) is herpes gladiatorum
[36]. This disease may involve the trigeminal, cervical, or lum-
bosacral dermatomes and is arbitrarily considered here. Com-
monly, HSV-1 is inoculated via abraded skin during the lock
position and lesions appear in 12 weeks. Recurrences are
frequent enough to be troublesome and may be unsightly, par-
ticularly when on the face, neck, and ears. Prophylactic use of
valacyclovir (500 or 1000 mg once or twice/day) during the
sports season has been helpful in such cases. The higher dose
regimen should be considered in cases of more recent primary
acquisition of infection (unpublished data) [37, 38].
Cervical and Thoracic Sensory Nerves Infections
Herpetic whitlow. This condition, caused by HSV-1 or -2,
is a painful infection of the digits seen predominantly in health
care professionals [39] (figure 2). Rowe et al. [40] reported that
the incidence of the disease is higher in dental personnel than
in the general population [40], although their study was done
before the routine use of disposable gloves in dental clinics.
Another study reported that of 46 patients seen by a dental
S74
Figure 2. Herpetic whitlow, an infection of the digits, seen primarily
in health care professionals.
hygienist over 4 days, 20 contracted gingivostomatitis. The hy-
gienist was subsequently found to have herpetic whitlow [41].
Primary and recurrent herpetic whitlows are often associated
with painful neuritis in the affected digit and forearm. The
condition may last 3 weeks or more and patients may benefit
from episodic or suppressive acyclovir. Several cases have been
successfully treated with intravenous acyclovir regimens, in-
cluding a 13-month-old girl [42] and a 35-year-old male dentist
[43]. While there have been no appropriate controlled clinical
trials with oral acyclovir or valacyclovir, the increased bioa-
vailability of valacyclovir can be expected to offer advantages
in dosage and perhaps efficacy in treating herpetic whitlow.
HSV infection of the nipple. Reports of HSV infection of
the nipple, while extremely uncommon, most often relate to
transmission of HSV from infant to mother during breast-feed-
ing [44]. Although treatment has not been defined in the lit-
erature, there is no reason to infer that acyclovir or valacyclovir
would be ineffective. If treatment of the mother were consid-
ered, dosages would be those recommended for HSV manage-
ment at other anatomic sites. Transfer of acyclovir to the infant
via breast milk should be recognized [45] but not be considered
a contraindication to treatment when the infection is severe.
HSV Infections of the Lumbosacral Sensory Nerves
Of primary importance in the neuroanatomic context is how
the organization of the peripheral sensory nervous system re-
lates not only to the pathogenesis but also to the diagnosis of
genital herpes. The sensory nerves arising from the sacral and
lower lumbar spinal segments innervate the genitalia in males
and females as well as a substantial part of the lower body,
including the buttocks, thighs, and perianal mucosa (figure 1).
As a consequence, when the lumbosacral ganglia become in-
fected with HSV, lesions can occur at seemingly very different
anatomic sites. The buttocks, thighs, and perianal mucosa are
common sites of recurrent blistering that may not always be
recognized as genital herpes without an understanding of the
Simmons JID 2002;186 (Suppl 1)
neuroanatomy involved. This is further compounded by the
fact that lesions are often atypical in appearance. In order to
maximize the chances of correct diagnosis and treatment, re-
current itching, burning, blistering, or erythema at any site
below the waist should be regarded as genital HSV infection
until proven otherwise. A swab taken from a recent eruption
is essential for confirmatory diagnosis. Serologic testing may
provide useful insight in diagnosing recurrent genital discom-
fort when the classic vesicular lesions of genital herpes are not
apparent. HSV-2 seroprevalence minimum estimates for general
adult populations, suggesting genital HSV infection, are about
5%25% in Western countries [46].
Two issues should be highlighted. First, perianal herpes does
not necessarily imply direct anal inoculation of HSV given in-
fection in lumbosacral sensory nerves. Second, symptomatic
Downloaded from http://jid.oxfordjournals.org/ by guest on May 18, 2016
herpes in the sacral dermatome may sometimes be accompanied
by asymptomatic shedding from the genital mucosa. The im-
portance of asymptomatic HSV reactivation and shedding in
sexual transmission of genital herpes and public health is re-
viewed elsewhere [47, 48].
To extend the neuroanatomic theme further, several cases
have been reported of HSV infections affecting the toes [42,
49, 50]. While it was generally assumed that autoinoculation
was the source of infection, it is likely that the sacral nerves of
the toes were responsible for the location of the lesions.
The role of antivirals in the management of genital herpes,
which effectively includes all HSV infections below the waist,
is discussed in detail elsewhere [51]. There have been several
recent advances in nucleoside analogues used for the treatment
of primary and recurrent genital herpes. In particular, vala-
cyclovir was found to be as effective as acyclovir in the acute
treatment of primary and recurrent infections, with the advan-
tage of a more convenient, twice daily dosing regimen [52, 53].
In addition, valacyclovir is effective when administered once
daily for suppressive management of recurrent genital herpes
[54, 55]. Ongoing research initiatives for new therapeutic strat-
egies in genital herpes focus on modification of the immune
response (e.g., by therapeutic vaccination or local immune re-
sponse modification) [56, 57] and on the potential for sup-
pressive antiviral therapy to influence sexual HSV transmission
risk [47].
Neonatal HSV infections, although rare, can have grave con-
sequences. Infection occurs via three distinct routes: in utero
infection, intrapartum contact, and postnatal acquisition. In
each case, although the mother is the most common source of
infection [3], there is usually no evidence of shedding at the
time of delivery [58]. Shedding may also occur from the uterine
cervix where lesions, if present, are hidden from view. Although
the safety and ease of administration of intravenous acyclovir
(10 mg/kg every 8 h) make it the treatment of choice for ne-
onatal HSV infection, recent discussions have identified the
ideal of prevention of infection [59]. Although it has been sug-
gested that prophylaxis with an antiviral agent should be of-
JID 2002;186 (Suppl 1) Scope of HSV Infections S75

fered to pregnant women who have a history of genital herpes

or are seropositive for HSV-2, this strategy highlights areas
where information is needed on the ability of nucleoside ana-
logues to interrupt vertical transmission of HSV infection and
on the safety of prolonged exposure of the preterm fetus to
antivirals.

Complications of HSV Infections of the Peripheral

Sensory Nervous System

Eczema herpeticum. HSV infection is a particularly trou-

blesome complication of atopic eczema [60] and frequently af-
fects the head and neck if associated with autoinoculation from
orolabial herpes (figure 3). Eczema herpeticum is a potentially
serious and progressive disease for which suppressive therapy

Downloaded from http://jid.oxfordjournals.org/ by guest on May 18, 2016

with acyclovir may be indicated. In some patients, recurrences
are so severe that they cannot be suppressed adequately with
acyclovir. Some cases have been managed successfully with sup-
pressive valacyclovir (1000 mg twice/day) (unpublished data).
Erythema multiforme and Stevens-Johnson syndrome. Er-
ythema multiforme, an acute, usually self-limiting inflamma-
tory syndrome, and Stevens-Johnson syndrome (SJS) are rec-
ognized as being part of a continuum of immunologically
mediated diseases of the skin. SJS is at the more severe end of
the spectrum. SJS is defined as erythema multiforme associated
with mucosal involvement, visceral involvement, or both, and
can be fatal. Viral infections including HSV-1 are recognized
as triggers for these severe cutaneous conditions [61]. The ef-
ficacy of continuous acyclovir therapy (600 mg twice/day for
6 months) in preventing outbreaks was demonstrated for re-
current erythema multiforme and in some cases resulted in com-
plete disease remission [61, 62].
Choy et al. [63] used suppressive acyclovir (200 mg twice/ Figure 3. Eczema herpeticum, a potentially serious and widespread
day) following acute treatment (200 mg 5 times/day) at the onset infection.
of herpetic oral lesions to treat a patient with recurrent HSV-
associated SJS. The interval between the onset of herpetic le- [65]. Progressive neurologic impairment is recognized as a se-
sions and erythema multiforme prior to acyclovir intervention quel to herpes simplex encephalitis [64]. It has been hypothe-
was 713 days. The patient was followed for 6 months (Feb- sized that this occurs as a result of accumulating damage caused
ruaryJuly) and, following acyclovir intervention, erythema by frequent reactivations of HSV in the brain. This issue is
multiforme did not occur in April, May, or July despite oral being studied in adults in a randomized controlled trial by
herpetic lesions in March, April, May, and July. Single-case following the initial intravenous treatment of encephalitis with
statistical analysis demonstrated a reduction of the HSV lesions a prolonged course of oral suppressive valacyclovir therapy
and erythema multiforme with acute and prophylactic acyclovir (Whitley R, personal communication). Two anecdotal reports
regimens. Although effective, the acyclovir regimens evaluated hint at the potential of this approach with valacyclovir for
in erythema multiforme and SJS might be improved by the prevention of further seizures [66, 67].
greater bioavailability of valacyclovir, which offers more con- The possibility of an association between acute episodes of
venient dosing and better control of HSV reactivation. multiple sclerosis (MS) and reactivations of herpesviruses con-
tinues to be a topic of interest. HSV, Epstein-Barr virus, and
human herpesvirus type 6 are all implicated [68]. In one study,
HSV Infections of the CNS
HSV-1 was detected in the blood of MS patients only during
Herpes simplex encephalitis is a life-threatening manifesta- acute episodes of the disease [65], suggesting that this virus
tion of infection usually caused by HSV-1 [64]. In neonates, reactivates during acute exacerbations of MS. However, it is
encephalitis accounts for 35% of babies with HSV infection unclear whether herpesvirus reactivation might precipitate the
S76 Simmons
episode. Further trials of antiviral compounds in MS patients
with dosage regimens that facilitate CNS penetration of active
15.
compounds seem warranted.
16.
Conclusions
17.
An intimate relationship with the sensory nervous system is
the common thread linking many manifestations of HSV in- 18.
fection. Acyclovir has been used to treat herpesvirus infections
for about 20 years and knowledge regarding its clinical utility 19.
is well documented. Acyclovir is highly specific for herpesvirus-
20.
infected cells and sets the standards for efficacy and safety. The
development of valacyclovir should ensure a less onerous treat-
ment schedule and better compliance, without loss in clinical 21.
benefit, alongside maintenance of the highly acceptable safety
profile of acyclovir. Future strategies for combating HSV are
22.
likely to continue through the search for effective vaccines and
immune modifying agents and ideally will target the control of
HSV infection at the level of the sensory nerve ganglia. 23.
References
1. World Health Organisation. Prevention and control of herpesvirus diseases. 24.
Part 1. Clinical and laboratory diagnosis and chemotherapy. A WHO
meeting. Bull World Health Organ 1985; 63:185201.
2. Whitley RJ, Gnann JW. The epidemiology and clinical manifestations of 25.
herpes simplex virus infections. In: Roizman B, Whitley RJ, Lopez C,
eds. The human herpesviruses. New York: Raven, 1993:69105.
3. Whitley RJ, Kimberlin DW, Roizman B. Herpes simplex viruses. Clin Infect 26.
Dis 1998; 26:54153.
4. Corey L, Spear PG. Infections with herpes simplex viruses. N Engl J Med
1986; 314:68691. 27.
5. Stevens JG. Human herpesviruses: a consideration of the latent state. Mi-
crobiol Rev 1989; 53:31832. 28.
6. Leib DA, Coen DM, Bogard CL, et al. Immediate-early regulatory gene
mutants define different stages in the establishment and reactivation of 29.
herpes simplex virus latency. J Virol 1989; 63:75968.
7. Mertz GJ, Coombs RW, Ashley R, et al. Transmission of genital herpes in
couples with one symptomatic and one asymptomatic partner: A pro- 30.
spective study. J Infect Dis 1988; 157:116977.
8. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus
type 2 infection in asymptomatic seropositive persons. N Engl J Med 31.
2000; 342:84450.
9. Cassidy KA, Whitley RJ. New therapeutic approaches to the alphaherpes-
virus infections. J Antimicrob Chemother 1997; 39:11928. 32.
10. Weller S, Blum MR, Doucette M, et al.. Pharmacokinetics of the acyclovir
pro-drug valaciclovir after escalating single- and multiple-dose adminis- 33.
tration to normal volunteers. Clin Pharmacol Ther 1993; 54:595605.
11. Lafferty WE, Coombs RW, Benedetti J, Critchlow C, Corey L. Recurrences 34.
after oral and genital herpes simplex virus infection: influence of site
infection and viral type. N Engl J Med 1987; 316:14449.
12. Amir J, Harel L, Smetana Z, Varsano I. Treatment of herpes simplex gin-
givostomatitis with aciclovir in children: a randomised double blind pla- 35.
cebo controlled study. BMJ 1997; 314:18003.
13. Huff JC, Krueger GG, Overall JC Jr, Copel J, Spruance SL. The histopath- 36.
ologic evolution of recurrent herpes simplex labialis. J Am Acad Dermatol
1981; 5:5507. 37.
14. Spruance SL, Overall JC, Kern ER, Krueger GG, Pliam V, Miller W. The
JID 2002;186 (Suppl 1)
natural history of recurrent herpes simplex labialis: implications for an-
tiviral therapy. N Engl J Med 1977; 297:6975.
Esmann J. The many challenges of facial herpes simplex virus infection. J
Antimicrob Chemother 2001; 47(Suppl 1):1727.
Bader C, Crumpacker CS, Schnipper LE, et al. The natural history of re-
current facial-oral infection with herpes simplex virus. J Infect Dis
1978; 138:897905.
Embil JA, Stephens RG, Manual FR. Prevalence of recurrent herpes labialis
and aphthous ulcers among young adults on six continents. Can Med
Assoc J 1975; 113:62730.
Fiddian AP, Yeo JM, Stubbings R, Dean D. Successful treatment of herpes
labialis with topical acyclovir. Br Med J (Clin Res Ed) 1983; 286:1699701.
Worrall G. Evidence for efficacy of topical acyclovir in recurrent herpes
labialis is weak. BMJ 1996; 313:46.
Raborn GW, McGaw WT, Grace M, Tyrrell LD, Samuels SM. Oral acyclovir
and herpes labialis: a randomized, double-blind, placebo-controlled study.
J Am Dent Assoc 1987; 115:3842.
Laiskonis A, Thune T, Neldam S, Hiltunen-Back E. Valacyclovir in the treat-
ment of facial herpes simplex virus infection. J Infect Dis 2002; 186(Suppl
Downloaded from http://jid.oxfordjournals.org/ by guest on May 18, 2016
1):S6670 (in this issue).
Rooney JF, Straus SE, Mannix ML, et al. Oral acyclovir to suppress fre-
quently recurrent herpes labialis. A double blind placebo-controlled trial.
Ann Intern Med 1993; 118:26872.
Baker DA, Deeter RG, Redder K, Phillips JA. Valacyclovir effective for
suppression of recurrent HSV-1 herpes labialis [abstract 464]. In: Program
and abstracts of the 40th Interscience Conference on Antimicrobial Agents
and Chemotherapy (Toronto). Washington, DC: American Society for
Microbiology, 2000.
Gilbert S, McBurney E. Use of valacyclovir for herpes simplex virus-1 (HSV-
1) prophylaxis after facial resurfacing: a randomized clinical trial of dosing
regimens. Dermatol Surg 2000; 26:504.
Gilbert S. Improving the outcome of facial resurfacingprevention of herpes
simplex virus type 1 reactivation. J Antimicrob Chemother 2001; 47(Suppl
1):2934.
Darougar S, Wishart MS, Viswalingam ND. Epidemiological and clinical
features of primary herpes simplex virus ocular infection. Br J Ophthalmol
1985; 69:26.
Falcon MG. Herpes simplex virus infections of the eye and their management
with acyclovir. J Antimicrob Chemother 1983; 12(Suppl B):3943.
Falcon MG. Rational acyclovir therapy in herpetic eye disease. Br J Ophthal-
mol 1987; 71:1026.
Sudesh S, Laibson PR. The impact of the herpetic eye disease studies on the
management of herpes simplex virus ocular infections. Curr Opin
Ophthalmol 1999; 10:2303.
Herpetic Eye Disease Study Group. Oral acyclovir for herpes simplex eye
disease: effect on prevention of epithelial keratitis and stromal keratitis.
Arch Ophthalmol 2000; 118:10306.
Harding SP, Rigal D, Easty D, Sarapa N, Weller S. Superior intraocular
penetration of aciclovir from valaciclovir in comparison with oral aciclo-
vir. J Antimicrob Chemother 1999; 44(Suppl A):16.
Poirier RH, Kingham JD, de Miranda P, Annel M. Intraocular antiviral
penetration. Arch Ophthalmol 1982; 100:19647.
Furuta Y, Fukuda S, Chida E, et al. Reactivation of herpes simplex virus
type 1 in patients with Bells palsy. J Med Virol 1998; 54:1626.
Adour KK, Ruboyianes JM, Von Doersten PG, et al. Bells palsy treatment
with acyclovir and prednisone compared with prednisone alone: a double-
blind, randomized, controlled trial. Ann Otol Rhinol Laryngol 1996; 105:
3718.
Grogan PM, Gronseth GS. Practice parameter: steroids, acyclovir, and sur-
gery for Bells palsy (an evidence-based review). Neurology 2001; 56:8306.
Belongia EA, Goodman JL, Holland EJ, et al. An outbreak of herpes gla-
diatorum at a high school wrestling camp. N Engl J Med 1991; 325:90610.
Anderson BJ. The effectiveness of valacyclovir in preventing reactivation of
herpes gladiatorum in wrestlers. Clin J Sport Med 1999; 9:8690.
JID 2002;186 (Suppl 1) Scope of HSV Infections
38. Anderson BJ. Valacyclovir for suppression of recurrent herpes gladiatorum
[abstract 465]. In: Program and abstracts of the 40th Interscience Con-
ference on Antimicrobial Agents and Chemotherapy (Toronto). Wash-
ington, DC: American Society for Microbiology, 2000.
39. Klotz RW. Herpetic whitlow: an occupational hazard. AANA J 1990; 58:
813.
40. Rowe NH, Heine CS, Kowalski CJ. Herpetic whitlow: an occupational dis-
ease in practising dentists. J Am Dent Assoc 1982; 105:4713.
41. Manzella JP, McConville JH, Valenti W, Menegus MA, Swierkosz EM, Arens
M. An outbreak of herpes simplex virus type 1 gingivostomatitis in a
dental hygiene practice. JAMA 1984; 252:201922.
42. Mohler A. Herpetic whitlow of the toe. J Am Board Fam Pract 2000; 13:
2135.
43. Schwandt NW, Mjos DP, Lubow RM. Acyclovir and the treatment of herpetic
whitlow. Oral Surg Oral Med Oral Pathol 1987; 64:2558.
44. Mercey D, Mindel A. Screening pregnant women for genital herpes. Biomed
Pharmacother 1990; 44:25762.
45. Meyer LJ, de Miranda P, Sheth N, Spruance S. Acyclovir in human breast
milk. Am J Obstet Gynecol 1988; 158:5867.
46. Smith J, Robinson NJ. Global review of the age-specific prevalence of in-
fection with herpes simplex virus types 1 and 2. J Infect Dis 2002; 186
(Suppl 1):S328 (in this issue).
47. Koelle DM, Wald A. Herpes simplex virus: the importance of asymptomatic
shedding. J Antimicrob Chemother 2000; 45(Suppl 3):18.
48. Corey L, Handsfield HH. Genital herpes and public health: addressing a
global problem. JAMA 2000; 283:7914.
49. Feder HM, Geller RW. Herpetic whitlow of the great toe. N Engl J Med
1992; 326:12956.
50. Egan LJ, Bylander JM, Agerter DC, Edson RS. Herpetic whitlow of the toe:
an unusual manifestation of infection with herpes type 2. Clin Infect Dis
1998; 26:1967.
51. Patel R. Progress in meeting todays demands in genital herpes: an overview
of current management. J Infect Dis 2002; 186(Suppl 1):S4756 (in this
issue).
52. Fife KH, Barbarash RA, Rudolph T, et al. Valaciclovir versus acyclovir in
the treatment of first-episode genital herpes infection: results of an inter-
national, multicenter, double-blind, randomized clinical trial. Sex Transm
Dis 1997; 24:4816.
53. Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus aciclovir in
patient initiated treatment of recurrent genital herpes: a randomised, dou-
ble blind clinical trial. Genitourin Med 1997; 73:1106.
54. Patel R, Bodsworth NJ, Woolley P, et al. Valaciclovir for the suppression of
recurrent genital HSV infection: a placebo controlled study of once daily
therapy. Genitourin Med 1997; 73:1059.
S77
55. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of
recurrent genital herpes simplex virus infection: a large-scale dose range-
finding study. J Infect Dis 1998; 178:60310.
56. Stanberry L, Cunningham AL, Mindel A, et al. Prospects for control of
herpes simplex virus disease through immunization. Clin Infect Dis
2000; 30:54966.
57. Spruance SL, Tyring S, Bleazard C, et al. Immunomodulation to decrease
recurrences of herpes genitalis: a double-blind, dose ranging study of
topical R-848 [abstract 466]. In: Program and abstracts of the 40th In-
terscience Conference on Antimicrobial Agents and Chemotherapy (To-
ronto). Washington, DC: American Society for Microbiology, 2000.
58. Brown ZA, Benedetti J, Ashley R, et al. Neonatal herpes simplex virus in-
fection in relation to asymptomatic maternal infection at the time of labor.
N Engl J Med 1991; 324:124752.
59. Pass R, Weber T, Whitley RJ, eds. Management strategies in herpes: her-
pesvirus infections in pregnancy. Worthing, UK: PAREXEL MMS Eu-
rope, 2000.
60. Bork K, Brauninger W. Increasing incidence of eczema herpeticum: analysis
Downloaded from http://jid.oxfordjournals.org/ by guest on May 18, 2016
of seventy-five cases. J Am Acad Dermatol 1988; 19:10249.
61. Schofield JK, Tatnall FM, Leigh IM. Recurrent erythema multiforme: clinical
features and treatment in a large series of patients. Br J Dermatol
1993; 128:5425.
62. Tatnall FM, Schofield JK, Leigh IM. A double-blind, placebo-controlled trial
of continuous acyclovir therapy in recurrent erythema multiforme. Br J
Dermatol 1995; 132:26770.
63. Choy AC, Yarnold PR, Brown JE, Kayaloglou GT, Greenberger PA, Pat-
terson R. Virus induced erythema multiforme and Stevens-Johnson syn-
drome. Allergy Proc 1995; 16:15761.
64. Davis LE, McLaren LC. Relapsing herpes simplex encephalitis following
antiviral therapy. Ann Neurol 1983; 13:1925.
65. Ferrante P, Mancuso R, Pagani E, et al. Molecular evidences for a role of
HSV-1 in multiple sclerosis clinical acute attack. J Neurovirol 2000;
6(Suppl 2):S10914.
66. Cornford ME, McCormick GF. Adult-onset temporal lobe epilepsy associ-
ated with smoldering herpes simplex 2 infection. Neurology 1997; 48:
42530.
67. Chan PK, Chow PC, Peiris JS, Mak AW, Huen KF. Use of valaciclovir in
a 12-year-old boy with herpes simplex encephalitis. Hong Kong Med J
2000; 6:11921.
68. Bergstrom T. Several options for antiviral treatment trials in multiple scle-
rosisbut which targets should be selected? Expert Opin Pharmacother
2000; 1:108790.